2020
DOI: 10.1007/s10067-020-05055-x
|View full text |Cite
|
Sign up to set email alerts
|

Cancer risks along the disease trajectory in antineutrophil cytoplasmic antibody associated vasculitis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
13
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6

Relationship

3
3

Authors

Journals

citations
Cited by 10 publications
(14 citation statements)
references
References 51 publications
1
13
0
Order By: Relevance
“…It is also necessary to further evaluate the drugs used to treat GPA and their impact on the mechanisms leading to carcinogenesis. There is a continued need for alternatives to CYC that are less toxic and for cancer screening in patients with a high risk of neoplasm development [58]. Bronchoscopy with biopsy and histopathological examination are crucial in proper differential diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…It is also necessary to further evaluate the drugs used to treat GPA and their impact on the mechanisms leading to carcinogenesis. There is a continued need for alternatives to CYC that are less toxic and for cancer screening in patients with a high risk of neoplasm development [58]. Bronchoscopy with biopsy and histopathological examination are crucial in proper differential diagnosis.…”
Section: Discussionmentioning
confidence: 99%
“…The Danish Renal Biopsy Registry found the incidence of cancer was rare in patients < 45 years with glomerular diseases but increased significantly beyond 45 years of age [36] . In patients with ANCA associated vasculitis, it was proposed that cancer screening should be based on the clinical context and supportive screening criteria, such as age ≥ 45 years, heavy current or ex-smokers, heavy alcohol users and patients with a history of previous cancer, concurrent hepatitis (HBV, HCV), human immunodeficiency virus (HIV) infections and significant family history of malignancy [11] . A further emphasis was mentioned for patients who had relapsing, or refractory glomerular disease treated with additional immunosuppressants that incurred a higher cumulative dose and longer duration as well as those who received a cumulative dose of >36g of cyclophosphamide.…”
Section: Cancer Screening In Glomerular Diseasementioning
confidence: 99%
“…Observational studies, case reports and case series have supported a link between glomerular disease and cancer. Some glomerular diseases require treatment with long-term immunosuppressants known to have oncogenic adverse effects and they may accelerate oncogenesis and neoplastic progression by direct mutagenesis or disruption in immune surveillance [8] , [9] , [10] , [11] , [12] . In addition, glomerular diseases associated with malignancy (paraneoplastic glomerulopathy) may be secondary complications of primary cancers and due to altered immune responses associated with cancer [13] , [14] , [15] , [16] .…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“… 6,8‐10 Studies suggested that the risk of cancer, including skin cancer, was increased in patients with all types of GD. 9,13 Risk factors for skin cancers in renal transplant are duration and intensity of immunosuppression, ultraviolet sun exposure, previous history of skin cancer, fair skin complexion or phototype, age at renal transplantation, smoking, male gender and viral infection with human papillomavirus 14 . Among these, a significant modifiable risk factor in skin cancer is the duration and intensity of exposure to ultraviolet radiation 15 …”
mentioning
confidence: 99%